Results 61 to 70 of about 740 (167)

Blastic Plasmacytoid Dendritic Cell Neoplasm in an Adolescent Managed in a Resource‐Limited Setting: A Case Report

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are rare, aggressive haematologic malignancies, uncommon in adolescents and often difficult to diagnose. We report a 16‐year‐old male presenting with lymphadenopathy, pancytopenia and constitutional symptoms.
Garrick Laudin, Jenifer Vaughan, Sugeshnee Pather, Claudia Summers, Avishkar Maney, Atul Lakha, Muhammed Faadil Waja, Lindokuhle Goqwana, Katherine Hodkinson, Kalyani Sen   +9 more
wiley   +1 more source

Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm

, 2020
BPDCN is ultimately a bone marrow disease requiring induction-type eradication therapy followed by hematopoietic stem cell transplant (HSCT) to achieve long-lasting remissions or cure.
Haddadin, Michael, Taylor, Justin
core   +1 more source

High ORRs Seen with Tagraxofusp-erzs in BPDCN [PDF]

Cancer Discovery, 2019
Abstract Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant.
openaire   +1 more source

Tissue‐Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts

American Journal of Hematology, Volume 100, Issue 12, Page 2305-2319, December 2025.
ABSTRACT Although all myeloid cells are considered to derive from hematopoietic stem cells, the cells in each myeloid lineage are heterogeneous populations, and their distribution and functions vary, depending on underlying physiologic and pathologic processes, age, sex, and genetic and epigenetic signatures.
Peter Valent, Johann Wojta, Petri T. Kovanen, Olivier Hermine, Falko Fend, Karl Sotlar, Hildegard Greinix, Klaus Geissler, Karin Hartmann, Juliana Schwaab, Marco Herling, Laura Boccuni, Lukas Kazianka, Max Vincent John, Wolfgang R. Sperr, Carina Zierfuss, Alexandar Tzankov, Christian Sillaber, Milen Minkov, Gregor Hoermann, Matthew Collin, Hans‐Peter Horny, Torsten Haferlach, Maria Sibilia, Julien Haroche, Paul La Rosée, Alberto Orfao, Michel Arock   +27 more
wiley   +1 more source

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies [PDF]

, 2020
CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy
Edouard Dupont, Paul, Shilpa, Hanadi El Achi, Khoury, Joseph D, Shilpa Paul, El Achi, Hanadi, Joseph D. Khoury, Dupont, Edouard   +7 more
core   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Elisabeth M. Walde, Edgar Jost, Amir S. Yazdi, David Kluwig   +4 more
wiley   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, Volume 19, Issue 11, Page 3376-3386, November 2025.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View [PDF]

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells.
Cosimo Di Raimondo, Claudia Paganini, Marco Galluzzo, Luca Bianchi, Flavia Lozzi, Pier Paolo Di Domenico, Elena Campione   +6 more
core   +2 more sources

A Multidisciplinary Approach to Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Practical Recommendations and Insights from Countries of the Gulf Cooperation Council. [PDF]

Cancers (Basel)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematopoietic malignancy characterized by cutaneous and systemic hematologic involvement.
Bakshi N, Al Hejazi A, Al-Maghraby H, Al Mugairi A, Alotaibi AS, Khogeer H, Seliem RM, Pandita R, Raslan H, Aung PP, Ohgami RS.   +10 more
europepmc   +2 more sources

The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis

Advanced Science, Volume 12, Issue 30, August 14, 2025.
This review summarizes recent advances in understanding the immune microenvironment's role in fibrosis, focusing on phenotypic/functional alterations of immune cells and their dynamic interactions with other cellular constituents within tissues. The authors further explore therapeutic opportunities and challenges in targeting immune microenvironment ...
Xiangqi Chen, Chuan Wu, Fei Tang, Jingyue Zhou, Li Mo, Yanping Li, Jinhan He   +6 more
wiley   +1 more source